NasdaqCM:PLSEMedical Equipment
Will Expanded nsPFA Pilot and Regulatory Progress Change Pulse Biosciences' (PLSE) Investment Narrative?
Pulse Biosciences recently reported a net loss of US$19.17 million for the second quarter ended June 30, 2025, alongside updates on its nsPFA technology programs and regulatory progress.
The company is advancing key clinical milestones, including expanding its pilot program for soft tissue ablation and preparing for pivotal trials in atrial fibrillation and benign thyroid disease.
We'll examine how the expanded pilot program for the nsPFA Percutaneous Electrode influences Pulse Biosciences’...